Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3328063 | Acta Haematologica Polonica | 2016 | 47 Pages |
New drugs introduced in recent years for the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. While therapeutic regimens based on bortezomib and thalidomide are recommended to most patients in first-line therapy, lenalidomide represents a cornerstone for treatment of relapsed/refractory myeloma patients. Most patients profit from prolonged treatment composed of consolidation and maintenance or treatment till progression. Beside concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease. In this article, we described also therapeutic recommendation for Waldenström macroglobulinemia and other plasmocytic dyscrasias.